drugset / Trial / NCT06094738

A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects

NCT06094738

Phase 1 Completed 30 enrolled Corcept Therapeutics
RandomizedCrossoverOpen-labelOther

Summary

The primary objective of the study is to evaluate the effects of a high-fat meal and of a low-fat meal on the bioavailability of relacorilant in healthy subjects.

Timeline

Start
2020-09-19
Primary completion
2020-11-16
Completion
2020-11-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Relacorilant Small molecule 400 mg Oral

Indications

No indication recorded.